Investigational drug · Phase 3
Lenbelintide
Also called: AZD6234
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity or Overweight, Obesity, Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
6 still active
All registered trials
3
Any phase or sponsor naming "Lenbelintide"
First trial start
2023
Sep 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lenbelintide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity or Overweight
- Obesity
- Overweight
- Type 2 Diabetes Mellitus
- Weight-Related Comorbidity
- With/Without Diabetes Mellitus, Type 2
- Overweight and Obesity
- Diabetes Mellitus, Type 2
- Obesity/Overweight
- Endocrinology
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Lenbelintide" as an intervention, largest first.
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07784725 · 2,500 participants (planned) · Start Aug 19, 2026 · Primary completion Aug 11, 2028
Drug: Lenbelintide; Placebo · For: Obesity or Overweight
Sites: Dothan, Alabama; Huntsville, Alabama; Mesa, Arizona · 220 sites in all
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07784270 · 1,500 participants (planned) · Start Aug 20, 2026 · Primary completion Aug 9, 2028
Drug: Lenbelintide; Placebo · For: Obesity or Overweight; Diabetes Mellitus, Type 2
Sites: Fairhope, Alabama; Huntsville, Alabama; Mobile, Alabama · 230 sites in all
- A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07776509 · 500 participants (planned) · Start Aug 24, 2026 · Primary completion Aug 9, 2028
Drug: Lenbelintide; Placebo · For: Obesity or Overweight; Weight-Related Comorbidity; With/Without Diabetes Mellitus, Type 2
Sites: Escondido, California; Lincoln, California; Walnut Creek, California · 96 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi A, le Roux CW · Diabetes Obes Metab 2026
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Bailey CJ, Flatt PR, Conlon JM · Peptides 2026
Also in development for Obesity or Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- AZD5004Phase 22 trials
AstraZeneca · Obesity or Overweight, Diabetes Mellitus, Type 2
- TifeglipronRO7795081, CT-996Phase 22 trials
Roche (Genentech) · Type 2 Diabetes Mellitus, Obesity or Overweight
- RGT001-075Phase 21 trial
Regor Pharmaceuticals Inc. · Obesity or Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.